Codagenix Appoints Johanna Kaufmann, Ph.D., Executive Vice President, Oncology to Lead Customization of Oncolytic Viruses for Solid Tumors
FARMINGDALE, N.Y., May 4, 2021 /PRNewswire/ — Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies for cancer, today announced the appointment of innovative oncology leader Johanna Kaufmann, Ph.D., as Executive Vice…
Comments Off on Codagenix Appoints Johanna Kaufmann, Ph.D., Executive Vice President, Oncology to Lead Customization of Oncolytic Viruses for Solid Tumors